DRAFT: May 9, 2019

First Quarter 2019 Results

 

Marrone Bio Innovations, Inc. Reports First-Quarter 2019 Financial Results

 

First-Quarter 2019 Revenues More Than Doubled to $8.7 Million, with

Gross Margins of 57 Percent

 

DAVIS, Calif. – May 9, 2019 – Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable biopesticide and plant health solutions, has provided its financial results for the first quarter ended March 31, 2019.

 

Selected Operating and Financial Highlights

 

$ in millions 

Q1

2019

  

Q1

2018

   % Increase (Decrease) 
Revenues  $8.7   $4.3    102%
Gross Profit  $5.0   $2.1    140%
Gross Margin   57.2%   48.1%   19%
Operating Expenses  $8.6   $7.6    14%
Loss from Operations  $(3.6)  $(5.5)   (34)%
Net Loss  $(3.9)  $(5.3)   (25)%
Cash Used in Operations  $7.7   $9.7    (22)%

 

Q1 2019 Financial Highlights

 

Revenues in the first quarter of 2019 improved by 102 percent to $8.7 million, compared with $4.3 million in the first quarter of 2018. The record quarterly sales were led by continued adoption of the Venerate family of products, both for foliar applications in vegetables and for soil- and seed-applied applications in row crops. Revenues also benefited from placement of Grandevo for in-season insect control in fruits and vegetables, as well as expanded market reach for Regalia to treat fungal diseases in trees, nuts and vines.
Gross margins reached 57.2 percent, benefiting from the higher net revenue and higher mix of the Venerate family of products and better manufacturing efficiencies.
The 14 percent increase in operating expenses reflected planned investments in the commercial organization and programs, and in field trials for key research and development projects, including a new proprietary biological herbicide. This increase was offset somewhat by a decrease in accounting and other professional consulting fees in the first quarter of 2019. 

 

 
 

 

Net loss in the first quarter of 2019 was $3.9 million, or $(0.04) per share, compared with a net loss of $5.3 million, or $(0.07) per share, in the first quarter of 2018.
On a comparative basis, the first quarter of 2018 included a non-recurring net benefit of $1.8 million to other income related to the Company’s comprehensive financing and debt restructuring transactions. Additionally, the diluted weighted-average shares outstanding in the first quarter of 2019 were 110.7 million shares, compared with 74.6 million shares in the first quarter of 2018.
Cash used in operations for the first quarter of 2019 was $7.7 million, compared with cash used in operations of $9.7 million in the first quarter of 2018. The use of operating cash in the first quarter of 2019 reflected greater working capital requirements related to increased sales.

 

Management Commentary

 

“We have put a solid foundation in place – technically, commercially and financially – to drive revenue growth this year and set the stage for longer term growth. Our first-quarter results are a solid start to what we believe can be a transformative year for Marrone Bio,” said Dr. Pam Marrone, chief executive officer of Marrone Bio Innovations.

 

“As we broaden our customer outreach and distribution network, we expand our ability to sell our products for multiple uses within a given crop,” she added. “We have the technical flexibility to offer our products in combination with complementary traditional agricultural solutions or with other compatible biocontrol or biostimulant offerings, thus enhancing our revenue-generating capabilities.”

 

Operational Highlights

 

  Regalia’s label in Brazil was expanded to control fungal and bacterial diseases on lettuces, carrots, papayas, mangoes, watermelons, sweet peppers and grapes.
  Regalia Maxx biofungicide was approved for use on cannabis in Canada.
  Distribution agreements for Regalia Maxx were reached with Plant Products, a full-service greenhouse supplier, for eastern and central Canada; and with TerraLink, a leading supplier of crop input products, for western Canada.
  Venerate CG label was approved by the California Department of Pesticide Regulation (DPR) for use on cannabis.

 

Conference Call and Webcast

 

Management will host an investor conference call at 1:30 p.m. PDT (4:30 p.m. EDT) today, May 9, 2019, to discuss Marrone Bio Innovations’ first quarter 2019 financial results and provide a corporate update, and will conclude with a Q&A from participants. To participate, please use the following information:

 

 
 

 

Q1 2019 Conference Call and Webcast
Date: Thursday, May 9, 2019
Time: 1:30 p.m. Pacific time (4:30 p.m. Eastern time)
U.S. Dial-in: 1-800-263-0877
International Dial-in: 1-323-794-2094
Conference ID: 7937030
Webcast: http://public.viavid.com/index.php?id=133556

 

Please dial in at least 10 minutes before the start of the call to ensure timely participation.

 

A playback of the call will be available through June 9, 2019. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally. Please use the replay pin number 7937030. A webcast will also be available for 30 days on the IR section of the Marrone Bio Innovations website or by clicking here: MBII Q1 2019 Webcast.

 

About Marrone Bio Innovations

 

Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI) strives to lead the movement to a more sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that support a better tomorrow for farmers, turf managers and consumers around the globe. MBI has screened over 18,000 microorganisms and 350 plant extracts, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies to rapidly develop seven effective and environmentally responsible pest management products to help customers operate more sustainably while uniquely improving plant health and increasing crop yields. Supported by a robust portfolio of over 400 issued and pending patents around its superior natural product chemistry, MBI’s currently available commercial products are Regalia®, Stargus® and Amplitude®, Grandevo®, Venerate®, Majestene® and Zelto®, Haven®, and Zequanox®, all of which are registered trademarks of Marrone Bio Innovations.

 

Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram.

 

Marrone Bio Innovations Forward Looking Statements

 

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include statements regarding management’s proposed deliverables for 2019, the Company’s positioning for becoming a commercial leader, and the potential benefits of the Company’s products. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including consumer, regulatory and other factors affecting demand for the Company’s products, any difficulty in marketing MBI’s products in global markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, and adverse decisions by regulatory agencies and other relevant third parties. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the Securities and Exchange Commission. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of new information, future events or otherwise.

 

Marrone Bio Innovations Contacts:

Pam Marrone, CEO and Founder

Jim Boyd, President and CFO

Telephone: +1 (530) 750-2800

Email: Info@marronebio.com

 

Investor Relations:

Greg Falesnik

Managing Director

MZ Group – MZ North America

Main: 949-385-6449

MBII@mzgroup.us

 

 
 

 

MARRONE BIO INNOVATIONS, INC.

Condensed Consolidated Balance Sheets

(In Thousands, Except Par Value)

 

   MARCH 31,   DECEMBER 31, 
   2019   2018 
   (Unaudited)     
Assets          
Current assets:          
Cash and cash equivalents  $13,586   $18,221 
Accounts receivable   8,759    2,720 
Inventories, net   7,554    8,224 
Prepaid expenses and other current assets   1,310    971 
Total current assets   31,209    30,136 
Property, plant and equipment, net   14,132    14,512 
Right of use assets, net   5,126     
Restricted cash   1,560    1,560 
Other assets   356    359 
Total assets  $52,383   $46,567 
           
Liabilities and stockholders’ equity          
Current liabilities:          
Accounts payable  $2,377   $1,692 
Accrued liabilities   7,015    6,871 
Deferred revenue, current portion   379    438 
Lease liability, current portion   752     
Debt, current portion, net   5,541    2,318 
Total current liabilities   16,064    11,319 
Deferred revenue, less current portion   2,327    2,399 
Lease liability, less current portion   4,607    - 
Debt, less current portion, net   11,732    11,819 
Debt due to related parties   7,300    7,300 
Other liabilities   776    794 
Total liabilities   42,806    33,631 
Commitments and contingencies (Note 10)          
Stockholders’ equity:          
Preferred stock: $0.00001 par value; 20,000 shares
authorized and no shares issued or outstanding at March
31, 2019 and December 31, 2018
        
Common stock: $0.00001 par value; 250,000 shares
authorized, 110,691 shares issued and outstanding as of
March 31, 2019 and December 31, 2018
   1    1 
Additional paid in capital   296,967    296,409 
Accumulated deficit (1)   (287,391)   (283,474)
Total stockholders’ equity   9,577    12,936 
Total liabilities and stockholders’ equity  $52,383   $46,567 

 

 
 

 

MARRONE BIO INNOVATIONS, INC.

Condensed Consolidated Statements of Operations

(In Thousands, Except Per Share Amounts)

(Unaudited)

 

   THREE MONTHS ENDED
MARCH 31,
 
   2019   2018 
Revenues:          
Product  $8,601   $4,224 
License   115    100 
Total revenues   8,716    4,324 
Cost of product revenues   3,729    2,242 
Gross profit   4,987    2,082 
Operating Expenses:          
Research, development and patent   2,942    2,534 
Selling, general and administrative   5,674    5,031 
Total operating expenses   8,616    7,565 
Loss from operations   (3,629)   (5,483)
Other income (expense):          
Interest expense   (306)   (1,119)
Interest expense, related parties       (434)
Change in fair value of financial instruments       (5,177)
Loss on extinguishment of debt, net (1)       (2,196)
Gain on extinguishment of debt, related party (1)       9,183 
Other income (expense), net   18    (31)
Total other income (expense), net   (288)   226 
Net loss  $(3,917)  $(5,257)
Basic and diluted net loss per common share:  $(0.04)   (0.07)
Weighted-average shares outstanding used in computing basic and diluted net loss per common share:   110,691    74,591 

 

 
 

 

MARRONE BIO INNOVATIONS, INC.

Condensed Consolidated Statements of Cash Flows

(In Thousands)

 

   THREE MONTHS ENDED
MARCH 31,
 
   2019   2018 
Cash flows from operating activities          
Net loss  $(3,917)  $(5,257)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   455    478 
Right of use assets amortization   199     
Share-based compensation   558    491 
Non-cash interest expense   73    611 
Change in fair value of financial instruments       5,177 
Loss on extinguishment of debt, net (1)       2,196 
Gain on extinguishment of debt, related party, net (1)       (9,183)
Net changes in operating assets and liabilities:          
Accounts receivable   (6,039)   (567)
Inventories   670    (220)
Prepaid Expenses and other assets   (336)   146 
Deferred cost of product revenues       2 
Accounts payable   726    (1,085)
Accrued and other liabilities   310    (793)
Accrued interest due to related parties       (1,614)
Lease Liability   (150)    
Deferred revenue   (199)   (128)
Net cash used in operating activities   (7,650)   (9,746)
Cash flows from investing activities          
Purchases of property, plant and equipment   (116)   (362)
Net cash used in investing activities   (116)   (362)
Cash flows from financing activities          
Proceeds from issuance of common stock, net of offering costs       21,820 
Proceeds from issuance of debt       2,000 
Proceeds from secured borrowings   6,714    3,520 
Reductions in secured borrowings   (3,511)   (3,194)
Repayment of debt   (72)   (67)
Net cash provided by financing activities   3,131    24,079 
Net increase (decrease) in cash and cash equivalents and restricted cash   (4,635)   13,971 
Cash and cash equivalents and restricted cash,
beginning of period
   19,781    2,833 
Cash and cash equivalents and restricted cash, end of period  $15,146   $16,804 
           
Supplemental disclosure of cash flow information          
Cash paid for interest  $223   $2,145 
Supplemental disclosure of non-cash investing and financing
activities
          
Property, plant and equipment included in accounts payable and accrued liabilities  $10   $200 
Embedded derivative liability associated with bridge loan  $   $573 
Conversion of debt to equity  $   $10,000 
Conversion of bridge loan (convertible note) to equity  $   $6,000 
Conversion of debt, related party to equity  $   $35,000 
Conversion of accrued liabilities into equity associated with the granting of restricted stock units  $   $205 

 

(1) The above includes revised numbers for the three months ended March 31, 2018 as disclosed in Note 16 to our accompanying Notes to Consolidated Financial Statements included in Part II-Item 8-“Financial Statements and Supplementary Data” of the Annual Report on Form 10-K filed on March 29, 2019.

 

 
 

 


The following information was filed by Marrone Bio Innovations Inc (MBII) on Thursday, May 9, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Marrone Bio Innovations Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Marrone Bio Innovations Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

FREE Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue for FREE

Log in with your credentials

or    

Forgot your details?

Create Account